ProfileGDS5678 / 1443819_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 69% 73% 69% 69% 69% 69% 68% 69% 69% 68% 69% 69% 69% 70% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 14.2240469
GSM967853U87-EV human glioblastoma xenograft - Control 24.6803973
GSM967854U87-EV human glioblastoma xenograft - Control 34.2177369
GSM967855U87-EV human glioblastoma xenograft - Control 44.3656969
GSM967856U87-EV human glioblastoma xenograft - Control 54.2213169
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 14.2292769
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.2346468
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 34.2260369
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 44.2308269
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 14.1823768
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 24.2560969
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 34.2299769
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.2277869
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 54.3073470